Investment Geography: Israel, United States
Nina Kjellson joined Canaan healthcare team in the Fall of 2015. She focuses on early-stage investments in biopharmaceuticals and digital health. Current investment themes include therapeutics for serious and underserved conditions such as cancer, autoimmune disease and life-threatening infections; patient/consumer engagement; and IT-enabled transformation of healthcare delivery. She is co-founder and co-chair of ConsumerMed.org, a forum to address the convergence of health care and consumer innovation and serves as a mentor to Blueprint Health, a digital health incubator and Springboard Life Sciences, an accelerator for healthcare companies driven by women entrepreneurs. She is a member of the advisory board for the Oliver Wyman Health Innovation Center.
Current investments include Cidara (CDTX), Eiger Biopharmaceuticals, Lycera Inc., Ocera (OCRX), Paratek (PRTK), Tizona Therapeutics and WellTok. She serves on the boards of Eiger, Lycera, Ocera and WellTok.
Previous investments include Labrys Biologics (acquired by Teva), Alt12 (acquired by Honest Company), Trius Therapeutics (TSRX; acquired by Cubist), CNS Therapeutics (acquired by Covidien), NovaCardia (acquired by Merck), and Aspreva (ASPV; acquired by Galenica).
Prior to Canaan, Nina was a General Partner at InterWest Partners where she had been investing in healthcare start-ups since 2002. Before InterWest, she was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.
Nina was born in Scandinavia and grew-up in the Northeast. Nina received a B.A. in human biology from Stanford University (1997). She makes her home in the Bay Area.
She serves on board of the California Family Health Council and the California Leadership Council for the Nature Conservancy.
Fund's investment verticals: digital media, communications, mobility, enterprise, bio-pharmaceuticals, medical devices, digital health, MedTech, diagnostics and infrastructure.
MEDIA ABOUT NINA KJELLSON